Prudential Financial Inc. Increases Holdings in Solventum Corporation $SOLV

Prudential Financial Inc. boosted its position in shares of Solventum Corporation (NYSE:SOLV) by 31.0% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 105,875 shares of the company’s stock after purchasing an additional 25,035 shares during the quarter. Prudential Financial Inc. owned about 0.06% of Solventum worth $8,030,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Independent Franchise Partners LLP grew its position in shares of Solventum by 263.1% during the 1st quarter. Independent Franchise Partners LLP now owns 5,820,724 shares of the company’s stock worth $442,608,000 after buying an additional 4,217,570 shares in the last quarter. Davis Selected Advisers grew its holdings in Solventum by 3.9% during the 2nd quarter. Davis Selected Advisers now owns 5,492,661 shares of the company’s stock worth $416,563,000 after acquiring an additional 204,523 shares in the last quarter. Boston Partners increased its position in Solventum by 9.2% during the 2nd quarter. Boston Partners now owns 3,670,757 shares of the company’s stock valued at $278,363,000 after purchasing an additional 308,784 shares during the period. Geode Capital Management LLC increased its position in Solventum by 1.0% during the 2nd quarter. Geode Capital Management LLC now owns 3,563,792 shares of the company’s stock valued at $269,116,000 after purchasing an additional 36,660 shares during the period. Finally, Northern Trust Corp raised its holdings in shares of Solventum by 3.3% in the 1st quarter. Northern Trust Corp now owns 1,807,674 shares of the company’s stock valued at $137,456,000 after purchasing an additional 58,373 shares in the last quarter.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on SOLV shares. Weiss Ratings reissued a “hold (c)” rating on shares of Solventum in a report on Thursday, October 30th. Piper Sandler increased their target price on Solventum from $94.00 to $98.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Zacks Research raised Solventum from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 15th. Jefferies Financial Group assumed coverage on Solventum in a research note on Thursday, September 11th. They set a “hold” rating and a $80.00 price objective for the company. Finally, Wells Fargo & Company lifted their target price on Solventum from $79.00 to $82.00 and gave the company an “equal weight” rating in a research note on Monday, September 15th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Solventum currently has an average rating of “Hold” and an average price target of $85.56.

Solventum Stock Down 1.1%

Solventum stock opened at $84.32 on Friday. Solventum Corporation has a 1-year low of $60.70 and a 1-year high of $86.81. The business has a fifty day moving average price of $73.77 and a 200-day moving average price of $73.64. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.50 and a quick ratio of 1.14. The stock has a market capitalization of $14.63 billion, a price-to-earnings ratio of 9.71, a PEG ratio of 9.00 and a beta of 0.48.

Solventum (NYSE:SOLV) last released its quarterly earnings results on Thursday, November 6th. The company reported $1.50 EPS for the quarter, beating analysts’ consensus estimates of $1.43 by $0.07. The company had revenue of $2.10 billion during the quarter, compared to analysts’ expectations of $2.05 billion. Solventum had a return on equity of 28.01% and a net margin of 18.13%.The firm’s revenue was up .7% compared to the same quarter last year. During the same period last year, the business posted $1.64 earnings per share. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. Equities research analysts forecast that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Solventum announced that its board has authorized a stock repurchase program on Thursday, November 20th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the company to buy up to 7.5% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s management believes its shares are undervalued.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.